Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
This article was originally published in Pharmaceutical Approvals Monthly
With two novel components included in Gilead's investigational four-drug, fixed-dose combination pill for HIV, the company has a full clinical program ahead of it - but the first Phase II results offer early signs of promise
You may also be interested in...
ViiV Healthcare will market the two companies' combined portfolio of 10 HIV drugs while also taking over a 17-compound R&D operation.
Citing a need for more data, the agency refuses to file an NDA for a pill combining ezetimibe (Zetia) and atorvastatin (Pfizer's Lipitor).
The opportunity for J&J's investigative non-nucleoside reverse transcriptase inhibitor may come at the expense of BMS, Gilead's partner on Atripla.